Table 4.

Subgroup analysis of the risk of serious ventricular arrhythmia associated with oral fluoroquinolones assessed in this study compared with cefixime for 1–7 days after the index date

	Cefixime	Ciprofloxacin	Levofloxacin	Ofloxacin	Moxifloxacin
History of cardiovascular disease
OR (95% CI) (IPTW)	Reference	0.61 (0.34 to 1.08)	0.96 (0.58 to 1.57)	0.47 (0.24 to 0.85)	2.36 (1.17 to 5.12)
Without cardiovascular disease
OR (95% CI) (IPTW)	Reference	0.79 (0.47 to 1.33)	0.86 (0.54 to 1.34)	0.36 (0.21 to 0.60)	1.63 (0.84 to 3.29)
Age ≥65
OR (95% CI) (IPTW)	Reference	0.78 (0.48 to 1.24)	1.06 (0.71 to 1.60)	0.36 (0.22 to 0.57)	2.04 (1.16 to 3.73)
Age<65
OR (95% CI) (IPTW)	Reference	0.64 (0.32 to 1.25)	0.96 (0.51 to 1.81)	0.84 (0.38 to 1.85)	1.59 (0.60 to 4.58)
Male
OR (95% CI) (IPTW)	Reference	0.61 (0.36 to 0.99)	0.82 (0.53 to 1.25)	0.53 (0.29 to 0.96)	1.91 (1.00 to 3.80)
Female
OR (95% CI) (IPTW)	Reference	0.62 (0.35 to 1.07)	0.89 (0.54 to 1.46)	0.33 (0.19 to 0.56)	1.79 (0.87 to 3.92)

IPTW, inverse probability of treatment weighting.